Back to News
Market Impact: 0.15
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026
Source: Business Wire
Healthcare & Biotech
Genentech said it will present new trial data on fenebrutinib, Ocrevus and Enspryng at MSToronto2026, the 10th ACTRIMS-ECTRIMS Meeting. The article provides no trial results, numerical data or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Sovereign wealth funds' China and Hong Kong investments surge 190% after a bruising slump
- Arcus Biosciences prices $250 million stock offering at $17.50
- AstraZeneca says U.S. FDA approves rare kidney disease drug
- UnitedHealth's Earnings Jumped 60%. Is the Comeback Stock a Buy, Sell, or Hold?
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Why is Intuitive Surgical stock tumbling today?